

Evonik announces price increase for polyurethane foam additives

September 29, 2017

Effective November 1, 2017, or as contract terms permit, Evonik will increase globally prices for all polyurethane additives. The increase will be 5–10% depending on product type including DABCO®, POLYCAT®, TEGOSTAB®, TEGOAMIN®, KOSMOS®, GORAPUR® release agents and ORTEGOL® products.

Contact

Dr. Jürgen Krauter

Head of Communications
Nutrition & Care
Phone +49 6181 59-6847
Fax +49 6181 59-76847
juergen.krauter@evonik.com

Stannous Octoate (KOSMOS® 29, DABCO® T9) will be dealt with separately.

Contact person specialized press

Christian Fürstenau

Head of Communications
Comfort & Insulation
Phone +49 201 173-2019
christian.fuerstenau@evonik.com

Evonik has worked diligently and will continue working to offset continuously rising raw material, energy, labour and transportation costs, however it is not possible to absorb all of these rising cost. Evonik will increase polyurethane additive prices in order to continue to meet the needs of its customers in the future.

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 35,000 employees.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around €4.3 billion in 2016.

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11
45128 Essen
Telefon +49 201 177-01
Fax +49 201 177-3475
Germany

www.evonik.com

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Management Board

Dr. Reiner Beste, Chairman
Dr. Hans Josef Ritzert
Michael Gattermann
Markus Schäfer

Registered office Essen
Registered court
Essen local court
Commercial registry B 25784
HR no. FN 431387 v